In the following sections, chaperone-dependent pharmacodynamic mechanisms of neuroprotection corresponding to the contribution of Sigma1R and BiP to the pathogenesis of neurodegenerative diseases will be analyzed. This evidence concerns the gene SIGMAR1 and neurodegenerative disease.